CJ Bioscience, Inc. (KOSDAQ: 311690)

Market Cap	104.70B
Revenue (ttm)	4.90B
Net Income (ttm)	-21.17B
Shares Out	9.11M
EPS (ttm)	-2,433.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,067
Open	11,630
Previous Close	11,710
Day's Range	11,430 - 11,790
52-Week Range	11,260 - 17,500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About CJ Bioscience

CJ Bioscience, Inc. provides microbiome research solutions to companies, hospitals, and individuals in the healthcare field in South Korea and internationally. Its solutions include TrueBac ID, a cloud analysis platform for the identification of microorganism; and EzBioCloud, a public data and analytics portal that offers taxonomy, ecology, genomics, metagenomics, and microbiome of bacteria and archaea. The company also provides Smilegut, a smile intestinal microbial monitoring service; and Smilebaby, a customized healthcare service, which offe...

• Industry: Computer Programming, Data Processing, And Other Computer Related Services
• Founded: 2009
• Employees: 137
• Stock Exchange: KOSDAQ
• Ticker Symbol: 311690

Financial Performance

In 2023, CJ Bioscience's revenue was 5.58 billion, an increase of 36.82% compared to the previous year's 4.07 billion. Losses were -22.91 billion, -34.37% less than in 2022.